Contrasting enGene (ENGN) and The Competition

enGene (NASDAQ:ENGN) is one of 439 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare enGene to related companies based on the strength of its institutional ownership, earnings, dividends, risk, valuation, profitability and analyst recommendations.

Dividends

enGene pays an annual dividend of $1.58 per share and has a dividend yield of 22.8%. enGene pays out -97.0% of its earnings in the form of a dividend. As a group, “Biotechnology” companies pay a dividend yield of 3.1% and pay out 3,700.3% of their earnings in the form of a dividend. enGene is clearly a better dividend stock than its rivals, given its higher yield and lower payout ratio.

Institutional and Insider Ownership

64.2% of enGene shares are owned by institutional investors. Comparatively, 31.0% of shares of all “Biotechnology” companies are owned by institutional investors. 13.7% of enGene shares are owned by company insiders. Comparatively, 22.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

enGene has a beta of -0.63, indicating that its stock price is 163% less volatile than the S&P 500. Comparatively, enGene’s rivals have a beta of 1.20, indicating that their average stock price is 20% more volatile than the S&P 500.

Valuation & Earnings

This table compares enGene and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
enGene	N/A	$104.74 million	-4.25
enGene Competitors	$157.05 million	-$16.32 million	76.85

enGene’s rivals have higher revenue, but lower earnings than enGene. enGene is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares enGene and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-63.25%	-5.65%
enGene Competitors	-11,730.62%	-124.79%	-23.87%

Analyst Ratings

This is a summary of recent recommendations for enGene and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	0	0	6	0	3.00
enGene Competitors	743	2388	5590	67	2.57

enGene currently has a consensus target price of $34.40, suggesting a potential upside of 420.42%. As a group, “Biotechnology” companies have a potential upside of 16.05%. Given enGene’s stronger consensus rating and higher possible upside, research analysts clearly believe enGene is more favorable than its rivals.

Summary

enGene beats its rivals on 10 of the 15 factors compared.

enGene Company Profile

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.